SCHEMBL6405360

SCHEMBL6405360

C=C1/C(=C/C=C2\CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](C)[C@H]1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 12/20 0.76
MAPT P10636 3/20 0.76
SMN1; SMN2 Q16637 2/20 0.76
NR1I2 O75469 1/20 0.76
ABCB11 O95342 1/20 0.76
GC P02774 1/20 0.76
PGR P06401 1/20 0.76
ADORA3 P0DMS8 1/20 0.76
RXRA P19793 1/20 0.76
CHRM3 P20309 1/20 0.76
CNR1 P21554 1/20 0.76
SLC6A2 P23975 1/20 0.76
HTR2C P28335 1/20 0.76
MAPK1 P28482 1/20 0.76
AGTR1 P30556 1/20 0.76
SLC6A4 P31645 1/20 0.76
ADRA1A P35348 1/20 0.76
PTGS2 P35354 1/20 0.76
OPRD1 P41143 1/20 0.76
OPRK1 P41145 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401945 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL10307585 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL3181793 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6407006 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6402298 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6403787 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL5873196 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL5872989 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL6401347 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11
SCHEMBL5873197 1.00 VDR (0.76) VDRMAPTSMN1; SMN2NR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032754-A1 5,6-Trans-2-alkylvitamin D derivatives HIROAKI TAKAYAMA 2005-02-10 US disclosed
US-20030092687-A1 5,6-Trans-2-alkylvitamin d derivatives HIROAKI TAKAYAMA (JP) 2003-05-15 US disclosed
EP-1284259-A1 5,6- i TRANS /i -2-ALKYLVITAMIN D DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092687-A1 5,6-Trans-2-alkylvitamin d derivatives VDR, CYP24A1, CYP2R1 VDR 1/4885MAPT 4613/4885SMN1; SMN2 4789/4885
US-20050032754-A1 5,6-Trans-2-alkylvitamin D derivatives VDR, CYP2R1, CYP24A1 VDR 1/4885MAPT 4629/4885SMN1; SMN2 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.